Optimizing the potential of antibody-drug conjugates in oncology

Ann Oncol. 2023 Nov;34(11):964-967. doi: 10.1016/j.annonc.2023.08.020. Epub 2023 Sep 19.

Authors

F Mosele¹, G Montagnac², B Pistilli³, F André⁴

Affiliations

¹ Department of Medical Oncology, Gustave Roussy, Villejuif; INSERM U981, Gustave Roussy, Villejuif. Electronic address: Mariafernanda.mosele@gustaveroussy.fr.
² INSERM U1279, Gustave Roussy, Villejuif.
³ Department of Medical Oncology, Gustave Roussy, Villejuif.
⁴ Department of Medical Oncology, Gustave Roussy, Villejuif; INSERM U981, Gustave Roussy, Villejuif; Faculty of Medicine, Université Paris-Saclay, Kremlin Bicêtre, France.

PMID: 37730120
DOI: 10.1016/j.annonc.2023.08.020

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal
Humans
Immunoconjugates* / therapeutic use
Medical Oncology

Substances

Immunoconjugates
Antibodies, Monoclonal